Literature DB >> 9169770

High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets.

G Harth1, B Y Lee, M A Horwitz.   

Abstract

Mycobacterium tuberculosis, the primary etiologic agent of tuberculosis, is the world's leading cause of death from a single infectious agent, and new vaccines and drugs to combat it are urgently needed. The major extracellular proteins of M. tuberculosis, which are released into its phagosome in macrophages, its host cells in humans, are leading candidates for a vaccine and prime targets for new drugs. However, the development of these biologicals has been hampered by the unavailability of large quantities of recombinant extracellular proteins identical to their native counterparts. In this report, we describe the heterologous expression and secretion of four major M. tuberculosis extracellular proteins (the 30-, 32, 16-, and 23.5-kDa proteins--the first, second, third, and eighth most abundant, respectively) in rapidly growing, nonpathogenic mycobacterial species. Multiple attempts to obtain secretion of the proteins by using Escherichia coli- and Bacillus subtilis-based expression systems were unsuccessful, suggesting that high-level expression and secretion of these Mycobacterium-specific proteins require a mycobacterial host. All four recombinant proteins were stably expressed from the cloned genes' own promoters at yields that were 5- to 10-fold higher than those observed for the native proteins. The four proteins were purified to apparent homogeneity from culture filtrates by ammonium sulfate precipitation and ion-exchange and molecular sieve chromatography. The recombinant proteins were indistinguishable from their native counterparts by multiple criteria. First, N-terminal amino acid sequence determination demonstrated that processing of the leader peptides was highly accurate. Second, sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis revealed identical migration patterns. Third, mass spectrometry analysis confirmed that differences in mass were < or = 5 Da. A homolog of the M. tuberculosis 30-kDa protein was identified in M. smegmatis by means of DNA analyses and immunoscreening. This is the first time that secretion of recombinant M. tuberculosis extracellular proteins in their native form has been achieved. This study opens the door to mass production of correctly processed and secreted extracellular proteins of M. tuberculosis in a heterologous host and allows ready evaluation of their biologic and immunologic function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169770      PMCID: PMC175322          DOI: 10.1128/iai.65.6.2321-2328.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  "ATG vectors' for regulated high-level expression of cloned genes in Escherichia coli.

Authors:  E Amann; J Brosius
Journal:  Gene       Date:  1985       Impact factor: 3.688

2.  A new method for predicting signal sequence cleavage sites.

Authors:  G von Heijne
Journal:  Nucleic Acids Res       Date:  1986-06-11       Impact factor: 16.971

Review 3.  Mechanism and control of transcription initiation in prokaryotes.

Authors:  W R McClure
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

4.  Production in B. subtilis of hepatitis B core antigen and a major antigen of foot and mouth disease virus.

Authors:  K Hardy; S Stahl; H Küpper
Journal:  Nature       Date:  1981-10-08       Impact factor: 49.962

5.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Cloning restriction fragments that promote expression of a gene in Bacillus subtilis.

Authors:  D M Williams; E J Duvall; P S Lovett
Journal:  J Bacteriol       Date:  1981-06       Impact factor: 3.490

7.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

8.  Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis.

Authors:  G Harth; B Y Lee; J Wang; D L Clemens; M A Horwitz
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  The 3'-terminal sequence of Escherichia coli 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding sites.

Authors:  J Shine; L Dalgarno
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

View more
  21 in total

1.  T-cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs.

Authors:  B Y Lee; M A Horwitz
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Microaerophilic induction of the alpha-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis.

Authors:  L E Desjardin; L G Hayes; C D Sohaskey; L G Wayne; K D Eisenach
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

3.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria.

Authors:  Deborah Mai; Jennifer Jones; John W Rodgers; John L Hartman; Olaf Kutsch; Adrie J C Steyn
Journal:  Assay Drug Dev Technol       Date:  2011-01-31       Impact factor: 1.738

5.  Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galic
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Subcellular localization of the Iitracellular survival-enhancing Eis protein of Mycobacterium tuberculosis.

Authors:  J L Dahl; J Wei; J W Moulder; S Laal; R L Friedman
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Immunostimulatory activity of recombinant Mycobacterium bovis BCG that secretes major membrane protein II of Mycobacterium leprae.

Authors:  Masahiko Makino; Yumi Maeda; Katsuya Inagaki
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

8.  Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry.

Authors:  Ying Ge; Mariam El-Naggar; Siu Kwan Sze; Han Bin Oh; Tadhg P Begley; Fred W McLafferty; Helena Boshoff; Clifton E Barry
Journal:  J Am Soc Mass Spectrom       Date:  2003-03       Impact factor: 3.109

9.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

10.  Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo.

Authors:  Günter Harth; Marcus A Horwitz
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.